<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495962</url>
  </required_header>
  <id_info>
    <org_study_id>10-008404</org_study_id>
    <nct_id>NCT01495962</nct_id>
  </id_info>
  <brief_title>The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy</brief_title>
  <official_title>The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Damage control laparotomy (DCL) is a life saving maneuver used with success in trauma and&#xD;
      acute general surgery patients. The technique involves source control of sepsis and&#xD;
      hemorrhage with an abbreviated laparotomy. In other words, the surgical procedure is cut&#xD;
      short to allow for resuscitation in the ICU after the immediately life threatening pathology&#xD;
      is treated. Planned re-exploration is then performed within 24-48 hours. It is at this&#xD;
      procedure that the injuries are reconstructed. This technique, unfortunately, has several&#xD;
      complications implicit with its use including wound infection, enterocutaneous fistula&#xD;
      formation, and intra-abdominal abscess development.[1] Additionally, in patients whom primary&#xD;
      fascial closure is not achieved, extensive abdominal wall reconstruction will be required in&#xD;
      6-12 months. The key for preventing these complications is definitive closure of the&#xD;
      abdominal fascia, however, 10-50% of patients will have a planned ventral hernia with an open&#xD;
      abdominal wound at dismissal [1,2] Proven methods for decreasing the rate of planned ventral&#xD;
      hernia utilize tension in the midline to counter the effects of lateral abdominal muscular&#xD;
      retraction.[3,4,5] Despite these improvements, however, the planned ventral hernia rate&#xD;
      continues to be substantial.[2] Botulinum toxin a (BTX) is an FDA approved neuron modulating&#xD;
      agent which has been used extensively in cosmetic, motor and pain disorders over the past 20&#xD;
      years [6,7]. The toxin blocks acetylcholine and pain modulator release (calcitonin gene&#xD;
      related peptide and substance P) from the pre-synaptic cholinergic nerve terminal. The&#xD;
      peptides are unable to bind at their motor end plate receptors through a process that cleaves&#xD;
      proteins involved in the transport protein cascade. This results in flaccid paralysis and&#xD;
      neuromodulation of the abdominal wall muscles resulting in reduced lateral tension and pain.&#xD;
      Theoretically, this could increase the rates of primary fascial closure, improve pain&#xD;
      sensation, decrease the rate of complications associated with open abdomens all while&#xD;
      lowering the costs and need for future abdominal wall reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to determine whether BTX will facilitate primary fascial closure after DCL.</measure>
    <time_frame>2 years</time_frame>
    <description>The primary endpoint is the rate of delayed primary fascial closure. Delayed primary fascial closure will be considered when the rectus abdominus fascia is directly approximated in the midline during the same hospitalization as the initial DCL without the use of mesh.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-invasive biomechanical testing results (surface wave elastography, traction index and durometry)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications (wound infection, fascial dehiscence, enterocutaneous fistula formation, acute renal failure, pneumonia)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall hospital cost</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total narcotic use (morphine equivalents)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABPS score</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Wound; Abdomen, Abdominal Wall</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin A injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Saline) injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Six 25 cc injection of Botulinum Toxin A</description>
    <arm_group_label>Botulinum Toxin A injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Normal Saline)</description>
    <arm_group_label>Placebo (Normal Saline) injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  male or female, aged â‰¥ 18 years or older&#xD;
&#xD;
          -  signed Informed Consent form by appropriate patient representative&#xD;
&#xD;
          -  undergone a DCL for trauma or acute general surgery&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  death prior to BTX injection&#xD;
&#xD;
          -  failure to achieve hemodynamic stability within 24 hours (stable or decreasing&#xD;
             vasopressor support within 6 hours in combination with a stable or improving base&#xD;
             deficit or lactate level)&#xD;
&#xD;
          -  Viable pregnancy&#xD;
&#xD;
          -  At risk populations (&lt;18 years of age, prisoners)&#xD;
&#xD;
          -  BMI &gt; 50&#xD;
&#xD;
          -  Pre-existing pareses (Amyotrophic Lateral Sclerosis, myopathies, motor&#xD;
             polyneuropathies&#xD;
&#xD;
          -  impaired neuromuscular transmission (Myasthenia Gravis, Lambert-Eaton Syndrome)&#xD;
&#xD;
          -  concurrent aminoglycoside use&#xD;
&#xD;
          -  chronic obstructive pulmonary disease&#xD;
&#xD;
          -  known metastatic malignancy&#xD;
&#xD;
          -  pre-existing cirrhosis&#xD;
&#xD;
          -  necrotizing fasciitis of the trunk&#xD;
&#xD;
          -  hypocoagulable state (INR &gt;1.5)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin D Zielinski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Dries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regions Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hosptial</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2011</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Martin D. Zielinski</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Damage Control Laparotomy</keyword>
  <keyword>Open Abdomen</keyword>
  <keyword>Botulinum Toxin A</keyword>
  <keyword>Primary Fascial Closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Abdominal Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

